The underlying etiology of aplastic anemia is unknown in the majority of patients, although medications, chemical exposure, or viral infections can be implicated in some. Genetic susceptibility to a variety of diseases has been shown and it has recently been suggested that aplastic anemia is more common in individuals who are HLA D M + than in the general population. To examine this question, we retrospectively analyzed the results of HLA-DR typing in 75 aplastic anemia patients who received antithymocyte globulin (ATG) therapy or an HLA-matched sibling bone marrow transplant at UCLA between 1978 and 1989. Thirty-one patients were DR2'. a 1.9-fold higher incidence than the expected number of 16.6 patients (P < .0005). Of the 37 patients who received DVANCES IN BONE marrow transplantation, better supportive care (eg, platelet transfusions and antibiotics), and more effective use of immunosuppressive therapies (eg, antithymocyte globulin [ATG] and cyclosporin A) have improved the duration and quality of life of patients with aplastic anemia."3 The underlying etiology of most cases of aplastic anemia is unknown, yet in certain circumstances, such as post-hepatitis virus infection or after drug exposure, only a subset of exposed individuals develop aplastic anemia. For certain drugs, eg, captopril, this may relate to drug metabolism because elderly patients andor those with renal insufficiency have a higher likelihood of developing aplastic anemia after exposure to the drug.4.' In clonazipine-induced agranulocytosis, an association with the HLA B38, DR4, DQ3 haplotype6 or with HLA B38 alone7 has been documented.
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Associations between various HLA types and autoimmune diseases have been reported and several series (from Switzerland, UK, and Japan) have suggested an association of aplastic anemia with HLA DR2, although in none of these studies did it reach statistical significance (ie, a P value of <.05).'"' HLA DR2 expression has also been suggested to predict for a response to immunosuppressive therapy such as ATG or cyclosporin A. Such an association could be very useful in deciding the appropriate therapy for a given patient, especially for those who may be at higher than normal risk for developing complications after allogeneic bone marrow transplantation. Aplastic anemia patients have been treated with ATG or bone marrow transplantation for more than a decade at UCLA,'"I3 and HLA DR typing has become widely performed, allowing correlative studies to be performed. We report the prevalence of various DR types in 75 aplastic anemia patients treated at UCLA and examine clinical outcome relative to the HLA-DR type.
A MATERIALS AND METHODS
Patients. Based on previous reports of an association of HLA DR2 with aplastic anemia, we retrospectively reviewed the results of HLA typing for all aplastic anemia patients who were treated at UCLA Medical Center from 1978 to 1989. Only patients enrolled on a therapeutic trial were evaluated and during this time clinical trials were ongoing using bone marrow transplantation, ATG (with or without androgens), and colony-stimulating factors such as gramlocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (K-3). HLA typing was generally performed during the Blood, Vol 84, No 3 (August l), 1994: pp 923-927 ATG, 33 were evaluable for a response; 14 patients had either a complete (4 patients) or partial (10 patients) response, for an overall response rate of 42.4%. Of the 14 DR2' patients who received ATG, 7 responded, for a 50% response rate, which is not significantly higher than the response rate for the DR2-patients (7 of 19 [36.8%1; P = .50). The median survival of patients who are DR2+ was slightly, but not significantly, longer than that of the DR2-patients in the ATG group ( P = .19). Although the incidence of HLA DR2 was clearly increased in these patients with aplastic anemia, response rates to ATG were not significantly dflerent in the DR2+ and DR2-patients. 0 1994 b y The American Society of Hematology.
course of related or unrelated bone marrow donor searches or to obtain HLA-matched platelets for transfusion. Patients with aplastic anemia referred to UCLA for a second opinion were not included in this study and elderly patients who received ATG therapy, but never required HLA-matched platelets, were not generally HLA typed. All HLA DR typing was performed using the standard National Institutes of Health two-stage microlymphocytotoxicity assay.I4 HLA-DR2 was serologically split into DR15 and DR16 in 1987 (and, more recently, DNA typing has further split them into additional subtypes). Patients that were either DR15' or DR16' were evaluated as DR2'. 0.017, which is based on the proportion of each ethnic group in the aplastic anemia patient population (there were no patients of Japanese background in the patient population). The control population samples chosen for this analysis were comparable to the ethnic composition of the aplastic anemia patients in Southern California evaluated at UCLA, although there are many difficulties in precisely defining a patient's ethnic background and ensuring that the control group is ideal. The expected number of DR2' for each ethnic group is equal to the total number of patients in that group times the probability of DR2+ for that particular ethnic group.
To account for random error in the control population antigen frequencies, comparisons of DR2+ frequencies in the aplastic anemia patients and the control population, stratified for race, were performed using the Mantel-Haenszel x ' statistical test. P values were not corrected for the number of antigens tested, because previous studies suggested an association with HLA DR2. Relative risk for the incidence of aplastic anemia in DR2+ versus DRT individuals was calculated as the case-control odds ratio using the MantelHaenszel estimation. The relationship between response to ATG and DR2 typing was examined individually by means of frequency table analysis using the two-tailed Fisher's exact test (as were all categorical variables) and in combination with gender, age, disease severity, disease duration before ATG, and the addition of either androgens or cyclosporin A to ATG using a standard multiple logistic regression (SASISTAT [version 6.041, Cary, NC). Actuarial survival was calculated using the product limit analysis of Kaplan and Meier.I7 Survival of the DR2+ and DR2-patients was compared using a twotailed, generalized Wilcoxon analysis.
RESULTS
Seventy-five patients received therapy for aplastic anemia at UCLA and had HLA-DR typing performed. Forty-five were male and 30 were female, with a median age of 25 years (range, 1 to 64 years). Forty-two patients were Caucasian, 22 were Hispanic, 6 were Oriental, and 5 were black. Thirtyone of the 75 patients were HLA DR2+ (41.3%). The expected number of HLA DR2' patients was 16.6 (22.1%) based on the expected frequencies of DR2 in the Caucasian, Hispanic, Oriental, and black populations, as shown in Table  1 . The actual number of DR2+ patients was significantly greater than the number expected using the hypothesized rates for the four races (P < .0005, Mantel-Haenszel x2 test). We also examined the relationships between expected and observed numbers of HLA DR4+ and DR1' patients, which were the next most common HLA DR types; no significant differences were observed (P = .l7 and P = .12, respectively), The relative risk of aplastic anemia in DR2' individuals versus DR2-individuals is 2.4 (with a 95% confidence interval [CI] of 1.5 to 3.9). Relative risks for each race were 1.8 for Caucasians (with a 95% C1 of 1.0 to 3.4), 4.0 for Hispanics (with a 95% C1 of 1.4 to 11.2), 4.5 for Orientals (with a 95% C1 of 0.9 to 22.5), and 2.9 for blacks (with a 95% C1 of 0.5 to 18.0).
Of the 37 aplastic anemia patients who received ATG, 25 were male and 12 were female (Table 2) . Their median age was 32 years (range, 5 to 64 years). Thirty-three of these 37 patients were evaluable for a response to ATG (ie, they survived at least 3 months post-ATG); 14 responded (42.4%), with either a complete response (4 patients) or a partial response (10 patients). In our multivariate analysis, response did not correlate with patient age or gender. As shown in Table 3 , response to ATG was not significantly affected by the addition of androgens or cyclosporin A ( P = .46), whereas responses to ATG were nearly significantly more common in patients with moderately severe disease ( P = .06) and in those with a duration of disease of less than 3 months ( P = .08).
Seven of the responders were DR2+ and 7 were DR2-. The 50% response rate in the HLA DR2+ patients (7 of 14) was not significantly different than the response rate for the HLA DR2-patients (7 of 19 [36.8%]; (P = S O , two-sided Fisher's exact test). We did not find a statistically significant relationship between HLA DR2 positivity and the severity of the aplastic anemia in these patients ( P = .39), nor was DR2 positivity associated with the specific immunosuppressive regimen used ( P = .64) or the duration of disease ( P = 37). We also examined the survival of patients receiving ATG therapy according to their HLA-DR status. The median survival of the group of DR2+ patients who received ATG is 3,700 ? 2,344 days versus 1,804 2 932 days for the DR2-patients (P = .19, two-tailed Wilcoxon test).
DISCUSSION
Although aplastic anemia is most frequently idiopathic, an immune mediated suppression of hematopoiesis can be implicated in at least half of the patients. An increased susceptibility to the development of aplastic anemia is thought to be present in certain individuals, but is not yet identifiable.
In this study, we confirm that HLA DR2 is overrepresented in patients with aplastic anemia. We have observed an increased incidence of D W + in a large group of racially heterogeneous aplastic anemia patients. The heterogeneity of the patient sample makes it more difficult to determine precisely how much more frequent DR2 is in aplastic anemia patients than in the general population. This reflects imprecision in determining the ethnicity of the patients and in identifying the most appropriate normal population to use for comparison. This heterogeneity is also a strength of our analysis, because these patients are much more heterogeneous than previously reported cohorts. Our data is consistent with the increased prevalence of DR2+ reported in the only other large study of aplastic anemia patients, which was from SwitFor personal use only. on October 22, 2017. by guest www.bloodjournal.org From zerland." In that series, 46% of 68 aplastic anemia patients were DR2+, compared with 25% of the 151 healthy unrelated individuals (P = .W14 uncorrected, P = .056 after adjustment for the number of statistical tests performed); the relative risk of aplastic anemia in DR2+ individuals was 2.72. The antigen frequency of DR2 was increased among the healthy siblings and in their parents, but the differences were not statistically significant after the appropriate statistical adjustments. A variety of factors have been examined for their ability to predict for a clinical response to ATG therapy, including the duration of aplastic anemia, disease severity, the presence of bone marrow inflammatory cells, or the in vitro production of y-interferon or other cytokines.18-z However, at the present time, none of these factors has consistently predicted for a response to ATG at multiple institutions. Two small studies have looked at both the prevalence of HLA DR2+ in aplastic anemia patients and its ability to predict for a response to immunosuppressive therapy. In a study of 26 Japanese patients with bone marrow failure states who received cyclosporine as first-line therapy, the presence of DR2 positivity correlated with a clinical response to cyclosporine, as measured by achieving red blood cell transfusion independence? The incidence of DR2 positivity in the 20 aplastic anemia patients was not significantly higher than in normal healthy individuals in that district (40% v 35%, respectively; P = .14). In another study, from Liverpool, UK,8 11 patients with severe idiopathic aplastic anemia were HLA-typed and received either ATG, cyclosporine or both. Fifty-four percent of the patients were DR2+, compared with a 29% prevalence in the general population (P = .07); all 6 of the DR2+ patients responded to immunosuppressive therapy, whereas only 2 of the 5 DR2-patients responded (P = .12). Thus, in this small group of patients no definitive statement could be made regarding the predictive value of DR2 positivity in predicting a response to ATG. In our larger study, the response rates For personal use only. on October 22, 2017. by guest www.bloodjournal.org From to ATG were not significantly different in the DR2+ patients (50%) than in the DR2-patients (36.8%) (P = SO). The odds ratio for responding to ATG in DR2+ patients compared with DR2-patients was 1.78, with broad confidence intervals (95% CI, 0.3 to 11.1). This was not significant in our logistic regression model (P = .53); however, the small numbers of patients in each group limited our ability to identify such a relationship, if it exists. Our ability to detect a 25% difference in response rates between the DR2+ and DR2-patients, with 95% probability, was only 20%, and our ability to detect a 50% difference in these two groups was only 74%.
The mechanism of action of ATG and of cyclosporine in the treatment of aplastic anemia remains unclear. Although both are referred to as immunosuppressive therapy, ATG has been shown to have a variety of immunostimulatory effects, including stimulating thymidine uptake, E -2 secretion, and the production of hematopoietic growth factors such as GM-CSF and IL-3.26,27 Thus, it is possible that HLA-DR2 predicts for a response to cyclosporin A ( a s reported by Nakao et al ' ) but not to ATG.
The recent identification of certain HLA DRB 1 genotypes has allowed stratification of rheumatoid arthritis patients into those with aggressive or nonaggressive disease, which may be useful in guiding therapy.28 However, it appears that clinical decisions regarding the use of immunosuppressive therapy versus bone marrow transplantation in aplastic anemia patients cannot be based on the presence or absence of DR2+. Examination of HLA DR2 genotypes may provide additional information that could be analyzed for its predictive value in this setting. Recent reports suggest a higher response rate to ATG plus cyclosporine than ATG alone:' and it may be possible to predict, using HLA DR typing, which patients benefit from the addition of the cyclosporine.
Similarly, sufficient numbers of patients have not yet been analyzed to determine whether the occurrence of DR2+ is particularly prevalent in patients whose aplastic anemia is related to a specific cause. Further study may identify individuals at high risk for the development of aplastic anemia and specific types of exposures could be avoided.
